Oncotelic Therapeutics Company Description
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.
It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-β2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies.
The company is headquartered in Agoura Hills, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Vuong Trieu |
Contact Details
Address: 29397 Agoura Road Agoura Hills, Delaware 91301 United States | |
| Phone | 650 635 7000 |
| Website | oncotelic.com |
Stock Details
| Ticker Symbol | OTLC |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US6283411097 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vuong Trieu Ph.D. | Chairman and Chief Executive Officer |
| Amit Shah | Chief Financial Officer |
| Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. | Chief Medical Officer ? Translation Medicine and Director |
| Saranjit Saund | CBO and GM of AI Division |
| Steven W. King | Consultant and Director |
| Dr. Larn Hwang | Chief Scientific Officer |
| Dr. Seymour Howard Fein M.D. | Chief Regulatory Officer and Chief Medical Officer |
| Burcak Beser | Chief Technology Officer of AI Division |